Glucotrack, Inc. Announces Reverse Stock Split October 22nd, 2026|Business Wire| RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)–Glucotrack Announce Reverse Stock Split. Please leave this field empty Subscribe to Our Newsletter We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information. Please check your Inbox or Spam folder now to confirm your subscription. Like this post? Share it! FacebookXLinkedInEmail Related Posts GoGoMeds Appoints Harish Panchal as Chief Executive Officer November 15th, 2026 | 0 Comments Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application November 15th, 2026 | 0 Comments Advanced eClinical Training Approved for New Jersey's Eligible Training Provider List November 14th, 2026 | 0 Comments Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting November 14th, 2026 | 0 Comments Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products November 13th, 2026 | 0 Comments Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 13th, 2026 | 0 Comments TherapeuticsMD Announces Third Quarter 2026 Financial Results November 13th, 2026 | 0 Comments Discount Finder Helps Customers Unlock More Prescription Savings November 13th, 2026 | 0 Comments Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026 November 13th, 2026 | 0 Comments Zai Lab Announces Participation in Investor Conferences in November 2026 November 13th, 2026 | 0 Comments Unified Women’s Healthcare Launches a New Initiative Aimed at Leveraging Routine OB/GYN Care to Identify Cardiovascular Risk Earlier and Connect More Women to Preventive Care November 13th, 2026 | 0 Comments Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer November 13th, 2026 | 0 Comments